Stay updated with breaking news from Nasdaq Sabs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The brokerage currently has a $6.00 target price on the stock. Separately, Chardan Capital reiterated a buy rating and issued a $25.00 price target on shares of SAB Biotherapeutics […]
SAB Biotherapeutics (NASDAQ:SABS – Free Report) had its target price raised by Chardan Capital from $3.00 to $25.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, HC Wainwright decreased their target price on shares of SAB Biotherapeutics from $10.00 to $6.00 and set […]
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage...
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report)’s stock price dropped 1.7% during mid-day trading on Thursday . The stock traded as low as $5.75 and last traded at $5.90. Approximately 4,952 shares traded hands during trading, a decline of 71% from the average daily volume of 17,130 shares. The stock had previously closed at […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report)’s stock price fell 1.7% during mid-day trading on Thursday . The company traded as low as $5.75 and last traded at $5.90. 4,952 shares changed hands during trading, a decline of 71% from the average session volume of 17,130 shares. The stock had previously closed at $6.00. […]